Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued on Wednesday, May 2nd. They presently have a $12.00 target price on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 96.40% from the company’s current price.
The analysts wrote, “of FSGS and VOS Studies in 2Q18; Affirm Buy Stock Data 05/01/2018 Price $5.27 Exchange NASDAQ Price Target $12.00 52-Week High $8.19 52-Week Low $4.41 Enterprise Value (M) $239.5 Market Cap (M) $413 Public Market Float (M) 45.3 Shares Outstanding (M) 84.1 3 Month Avg Volume 606,874 Short Interest (M) 8.08 Balance Sheet Metrics Cash (M) $173.5 Total Debt (M) $0.0 Total Cash/Share $2.06 Book Value/Share $2.01 EPS Diluted Full Year – Dec 2016A 2017A 2018E 1Q (0.13) (0.92) (0.17) 2Q (0.10) (0.03) (0.21) 3Q (0.21) (0.16) (0.23) 4Q (0.21) (0.04) (0.24) FY (0.66) (0.92) (0.84) Revenue ($M) Full Year – Dec 2016A 2017A 2018E 1Q 0.1 0.0 0.0 2Q 0.1 0.3 0.0 3Q 0.0 0.0 0.0 4Q 0.0 0.0 0.0 FY 0.2 0.4 0.1 9 8 7 6 5 4 MAY-17 SEP-17 DEC-17 MAY-18 10 8 6 4 2 0 Vol. (mil) Price Phase 3 AURORA study progressing well and on track. The pivotal AURORA study evaluating voclosporin for the treatment of lupus nephritis (LN) remains on track to complete enrollment in 4Q18.””
A number of other equities research analysts have also recently commented on AUPH. Zacks Investment Research cut shares of Isotechnika Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. BidaskClub upgraded shares of Isotechnika Pharma from a “strong sell” rating to a “sell” rating in a research report on Friday, January 5th. ValuEngine upgraded shares of Isotechnika Pharma from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Royal Bank of Canada began coverage on shares of Isotechnika Pharma in a research report on Thursday, February 8th. They set an “outperform” rating and a $9.00 price objective on the stock. Finally, Cantor Fitzgerald set a $16.00 price objective on shares of Isotechnika Pharma and gave the company an “overweight” rating in a research report on Thursday, March 15th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $10.92.
Isotechnika Pharma opened at $6.11 on Wednesday, according to MarketBeat Ratings. Isotechnika Pharma has a 12 month low of $6.28 and a 12 month high of $6.64. The company has a market cap of $534.57 million, a price-to-earnings ratio of -6.64 and a beta of 2.26.
Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Thursday, May 10th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). Isotechnika Pharma had a negative return on equity of 20.67% and a negative net margin of 8,193.08%. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.05 million. equities analysts forecast that Isotechnika Pharma will post -0.7 earnings per share for the current year.
Institutional investors and hedge funds have recently modified their holdings of the company. Stifel Financial Corp raised its holdings in shares of Isotechnika Pharma by 98.4% in the first quarter. Stifel Financial Corp now owns 21,718 shares of the biotechnology company’s stock valued at $113,000 after acquiring an additional 10,772 shares in the last quarter. Spark Investment Management LLC acquired a new position in shares of Isotechnika Pharma during the fourth quarter valued at about $153,000. DRW Securities LLC acquired a new position in shares of Isotechnika Pharma during the first quarter valued at about $162,000. Wells Fargo & Company MN increased its holdings in shares of Isotechnika Pharma by 13,197.5% during the third quarter. Wells Fargo & Company MN now owns 26,595 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 26,395 shares in the last quarter. Finally, Cutler Capital Management LLC boosted its position in Isotechnika Pharma by 25.0% in the fourth quarter. Cutler Capital Management LLC now owns 50,000 shares of the biotechnology company’s stock valued at $226,000 after buying an additional 10,000 shares during the last quarter. 28.58% of the stock is owned by hedge funds and other institutional investors.
About Isotechnika Pharma
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has partnership agreements with Paladin Labs Inc and 3SBio, Inc The company was formerly known as Isotechnika Pharma Inc and changed its name to Aurinia Pharmaceuticals Inc in October 2013.
Receive News & Ratings for Isotechnika Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isotechnika Pharma and related companies with MarketBeat.com's FREE daily email newsletter.